Severity assessment tools in CAP

European Respiratory Monograph

Volumn 63, Issue , 2014, Pages 88-104

  Sintes, Helena ^a   Sibila, Oriol ^a,b   Waterer, Grant W ^c,d   Chalmers, James D ^e  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d Lung Institute of Western Australia   (Australia)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; COPEPTIN; D DIMER; ENDOTHELIN 1; HYDROCORTISONE; HYPERTENSIVE FACTOR; PROADRENOMEDULLIN; PROCALCITONIN; TROPONIN;

ACIDOSIS; ALBUMIN BLOOD LEVEL; AMERICAN THORACIC SOCIETY; APACHE; ARTERIAL PH; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BREATHING RATE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; COMMUNITY ACQUIRED PNEUMONIA; DIABETES MELLITUS; DISEASE SEVERITY; HUMAN; HYPOXEMIA; INFECTIOUS DISEASES SOCIETY OF AMERICA; LEUKOCYTE COUNT; MORTALITY; OXYGEN DESATURATION; PLEURA EMPYEMA; PNEUMONIA SEVERITY INDEX; PRACTICE GUIDELINE; SYSTOLIC BLOOD PRESSURE; THORAX RADIOGRAPHY; UREA BLOOD LEVEL;

EID: 84905728147     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10003613     Document Type: Article

References (116)

1. Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997; 157: 1709-1718.
2. Akram AR, Chalmers JD, Hill AT. Predicting mortality with severity assessment tools in out-patients with community-acquired pneumonia. QJM2011; 104: 871-879.
3. Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002; 166: 717-723.
4. Rodríguez A, Mendia A, Sirvent JM, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007; 35: 1493-1498.
5. Restrepo MI, Anzueto A. Severe community-acquired pneumonia. Infect Dis Clin North Am 2009; 23: 503-520.
6. Woodhead M, Welch CA, Harrison DA, et al. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17, 869 cases in the ICNARC Case Mix Programme Database. Crit Care 2006; 10: Suppl. 2, S1.
7. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67: 71-79.
8. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
9. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl. 2, S27-S72.
10. Lim WS, Lewis S, Macfarlane JT. Severity prediction rules in community acquired pneumonia: a validation study. Thorax 2000; 55: 219-223.
11. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-382.
12. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with communityacquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754.
13. Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47: 375-384.
14. España PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006; 174: 1249-1256.
15. Rello J, Rodriguez A, Lisboa T, et al. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med 2009; 37: 456-462.
16. Renaud B, Labarère J, Coma E, et al. Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: development of an international prediction rule. Crit Care 2009; 13: R54.
17. Buising KL, Thursky KA, Black JF, et al. Identifying severe community-acquired pneumonia in the emergency department: a simple clinical prediction tool. Emerg Med Australas 2007; 19: 418-426.
18. Chalmers JD, Singanayagam A, Akram AR, et al. Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia. J Antimicrob Chemother 2011; 66: 416-423.
19. Capelastegui A, España PP, Quintana JM, et al. Development of a prognostic index for 90-day mortality in patients discharged after admission to hospital for community-acquired pneumonia. Thorax 2009; 64: 496-501.
20. Chalmers JD, Singanayagam A, Murray MP, et al. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. Thorax 2009; 64: 592-597.
21. Falguera M, Trujillano J, Caro S, et al. A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. Clin Infect Dis 2009; 49: 409-416.
22. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64: Suppl. 3, iii1-iii55.
23. Sibila O, Restrepo MI, Anzueto A. What is the best antimicrobial treatment for severe community-acquired pneumonia (including the role of steroids and statins and other immunomodulatory agents). Infect Dis Clin North Am 2013; 27: 133-147.
24. Buising KL, Thursky KA, Black JF, et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 2006; 61: 419-424.
25. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002; 162: 1059-1064.
26. Bauer TT, Welte T, Strauss R, et al. Why do nonsurvivors from community-acquired pneumonia not receive ventilatory support?Lung 2013; 191: 417-424.
27. Marrie TJ, Fine MJ, Kapoor WN, et al. Community-acquired pneumonia and do not resuscitate orders. JAm Geriatr Soc 2002; 50: 290-299.
28. Chalmers JD. ICU admission and severity assessment in community-acquired pneumonia. Crit Care 2009; 13: 156.
29. Chalmers JD, Mandal P, Singanayagam A, et al. Severity assessment tools to guide ICU admission in communityacquired pneumonia: systematic review and meta-analysis. Intensive Care Med 2011; 37: 1409-1420.
30. Wunsch H, Angus DC, Harrison DA, et al. Comparison of medical admissions to intensive care units in the United States and United Kingdom. Am J Respir Crit Care Med 2011; 183: 1666-1673.
31. Restrepo MI, Mortensen EM, Rello J, et al. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010; 137: 552-557.
32. Renaud B, Santin A, Coma E, et al. Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia. Crit Care Med 2009; 37: 2867-2874.
33. Simpson JC, Macfarlane JT, Watson J, et al. A national confidential enquiry into community acquired pneumonia deaths in young adults in England and Wales. British Thoracic Society Research Committee and Public Health Laboratory Service. Thorax 2000; 55: 1040-1045.
34. Cillóniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011; 66: 340-346.
35. Singanayagam A, Chalmers JD. Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia. Lancet Respir Med 2013; 1: 653-662.
36. Alfrageme I, Aspa J, Bello S, et al. Normativas para el diagnostico y el tratamiento de la neumonia adquirida en la comunidad. Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR) [Guidelines for the diagnosis and management of community-acquired Pneumonia. Spanish Sociaty of Pulmonology and Thoracic surgery (SEPAR)]. Arch Bronconeumol 2005; 41: 272-289.
37. Working Group of the South African Thoracic Society. Management of community-acquired pneumonia in adults. S Afr Med J2007; 97: 1296-1306.
38. Tang CM, Macfarlane JT. Early management of younger adults dying of community-acquired pneumonia. Respir Med 1993; 87: 289-294.
39. Neill AM, Martin IR, Weir R, et al. Community-acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51: 1010-1016.
40. Singanayagam A, Chalmers JD, Hill AT. Severity assessment in community-acquired pneumonia. QJM2009; 102: 379-388.
41. Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax 2010; 65: 878-883.
42. Chalmers JD, Akram AR, Hill AT. Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis. Eur Respir J2011; 37: 858-864.
43. Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med 1998; 158: 1350-1356.
44. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of communityacquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283: 749-755.
45. Carratalà J, Fernández-Sabé N, Ortega L, et al. Outpatient care compared with hospitalization for communityacquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med 2005; 142: 165-172.
46. Renaud B, Coma E, Labarere J, et al. Routine use of the Pneumonia Severity Index for guiding the site-oftreatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study. Clin Infect Dis 2007; 44: 41-49.
47. Yealy DM, Auble TE, Stone RA, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomised controlled trial. Ann Intern Med 2005; 143: 881-894.
48. Lee RW, Lindstrom ST. A teaching hospital's experience applying the Pneumonia Severity Index and antibiotic guidelines in the management of community-acquired pneumonia. Respirology 2007; 12: 754-758.
49. Kaplan V, Angus DC, Griffin MF, et al. Hospitalized community-acquired pneumonia in the elderly: age-and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002; 165: 766-772.
50. Ewig S, Birkner N, Strauss R, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 1062-1069.
51. Valencia M, Badia JR, Cavalcanti M, et al. Pneumonia severity index class V patients with community-acquired pneumonia: characteristics, outcomes and value of severity scores. Chest 2007; 132: 515-522.
52. Restrepo MI, Mortensen EM, Pugh JA, et al. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J2006; 28: 346-351.
53. Yende S, van der Poll T, Lee M, et al. The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies. Thorax 2010; 65: 870-877.
54. Man SY, Lee N, Ip M, et al. Prospective comparison of three predictive rules for assessing severity of communityacquired pneumonia in Hong Kong. Thorax 2007; 62: 348-353.
55. Choudhury G, Chalmers JD, Mandal P, et al. Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients. Eur Respir J2011; 38: 643-648.
56. Aliberti S, Ramirez J, Cosentini R, et al. Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia. Respir Med 2011; 105: 1732-1738.
57. Ewig S, Welte T. CRB-65 for the assessment of pneumonia severity: who could ask for more?Thorax 2008; 63: 665-666.
58. Bont J, Hak E, Hoes AW, et al. Predicting death in elderly patients with community-acquired pneumonia: a prospective validation study reevaluating the CRB-65 severity assessment tool. Arch Intern Med 2008; 168: 1465-1468.
59. Francis NA, Cals JW, Butler CC, et al. Severity assessment for lower respiratory tract infections: potential use and validity of the CRB-65 in primary care. Prim Care Respir J2012; 21: 65-70.
60. Jones BE, Jones J, Bewick T, et al. CURB-65 pneumonia severity assessment adapted for electronic decision support. Chest 2011; 140: 156-163.
61. Charles PG, Davis JS, Grayson ML. Rocket science and the Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) guidelines for severe community-acquired pneumonia. Clin Infect Dis 2009; 48: 1796.
62. Phua J, See KC, Chan YH, et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax 2009; 64: 598-603.
63. Chalmers JD, Taylor JK, Mandal P, et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis 2011; 53: 503-511.
64. Sibila O, Mortensen EM, Redrow G, et al. Evaluation of the IDSA/ATS minor criteria for severe communityacquired pneumonia. Hosp Pract (1995)2012; 40: 158-164.
65. Sibila O, Meduri GU, Mortensen EM, et al. Improving the 2007 Infectious Disease Society of America/American Thoracic Society severe community-acquired pneumonia criteria to predict intensive care unit admission. J Crit Care 2013; 28: 284-290.
66. Kontou P, Kuti JL, Nicolau DP. Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused byStreptococcus pneumoniae. Am J Emerg Med 2009; 27: 968-974.
67. Brown SM, Jones BE, Jephson AR, et al. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med 2009; 37: 3010-3016.
68. Salih W, Schembri S, Chalmers JD. Simplification of the IDSA/ATS criteria for severe community-acquired pneumonia using meta-analysis and observational data. Eur Respir J 2013 [In press DOI: 10. 1183/09031936. 00089513].
69. Chalmers JD, Singanayagam A, Hill AT. Predicting the need for mechanical ventilation and/or inotropic support for young adults admitted to the hospital with community-acquired pneumonia. Clin Infect Dis 2008; 47: 1571-1574.
70. Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms genetic sepsis and early waning scores in predicting mortality in community-acquired pneumonia. Thorax 2007; 62: 253-259.
71. Menéndez R, Martínez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009; 64: 587-591.
72. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000; 28: 68-73.
73. Müller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007; 7: 10.
74. Krüger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J2008; 31: 349-355.
75. Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in communityacquired pneumonia. Ann Emerg Med 2008; 52: 48-58.
76. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelinesvsstandard guidelines on antibiotic use in lower respiratory tract infections: The ProHOSP randomized controlled trial. JAMA2009; 302: 1059-1066.
77. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 84-93.
78. Huang DT, Angus DC, Kellum JA, et al. Midregional proadrenomedullin as a prognostic tool in communityacquired pneumonia. Chest 2009; 136: 823-831.
79. Volanakis JE, Kaplan MH. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc Soc Exp Biol Med 1971; 136: 612-614.
80. Smith RP, Lipworth BJ, Cree IA, et al. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest 1995; 108: 1288-1291.
81. García Vázquez E, Martínez JA, Mensa JA, et al. C-reactive protein levels in community-acquired pneumonia. Eur Respir J2003; 21: 702-705.
82. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008; 121: 219-225.
83. Lee JH, Kim J, Kim K, et al. Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia. J Crit Care 2011; 26: 287-294.
84. Hohenthal U, Hurme S, Helenius H, et al. Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia. Clin Microbiol Infect 2009; 15: 1026-1032.
85. Hirata Y, Mitaka C, Sato K, et al. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrinol Metab 1996; 81: 1449-1453.
86. Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides 2001; 22: 1693-1711.
87. Jougasaki M, Burnett JC Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci 2000; 66: 855-872.
88. Kato J, Tsuruda T, Kitamura K, et al. Adrenomedullin: a possible autocrine or paracrine hormone in the cardiac ventricles. Hypertens Res 2003; 26: Suppl, S113-S119.
89. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Crit Care 2006; 10: R96.
90. Schuetz P, Wolbers M, Christ-Crain M, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 2010; 14: R106.
91. Guignant C, Voirin N, Venet F, et al. Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med 2009; 35: 1859-1867.
92. Bello S, Lasierrra AB, Mincholé E, et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J2012; 39: 1144-1155.
93. Ginsberg JS, Wells PS, Kearon C, et al. Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism. Ann Intern Med 1998; 129: 1006-1011.
94. Wada H, Sakuragawa N, Mori Y, et al. Hemostatic molecular markers before the onset of disseminated intravascular coagulation. Am J Hematol 1999; 60: 273-278.
95. Shilon Y, Shitrit AB, Rudensky B, et al. A rapid quantitative D-dimer assay at admission correlates with the severity of community acquired pneumonia. Blood Coagul Fibrinolysis 2003; 14: 745-748.
96. Querol-Ribelles JM, Tenias JM, Grau E, et al. Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest 2004; 126: 1087-1092.
97. Kollef MH, Eisenberg PR, Shannon W. A rapid assay for the detection of circulating D-dimer is associated with clinical outcomes among critically ill patients. Crit Care Med 1998; 26: 1054-1060.
98. Chalmers JD, Singanayagam A, Scally C, et al. Admission D-dimer can identify low-risk patients with community-acquired pneumonia. Ann Emerg Med 2009; 53: 633-638.
99. Milbrandt EB, Reade MC, Lee M, et al. Prevalence and significance of coagulation abnormalities in communityacquired pneumonia. Mol Med 2009; 15: 438-445.
100. Snijders D, Schoorl M, Schoorl M, et al. D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical trial. Eur J Intern Med 2012; 23: 436-441.
101. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
102. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J1999; 138: 285-290.
103. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-167.
104. Mueller C, Laule-Kilian K, Scholer A, et al. B-type natriuretic peptide for risk stratification in communityacquired pneumonia. J Intern Med 2005; 258: 391-393.
105. Christ-Crain M, Breidthardt T, Stolz D, et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med 2008; 264: 166-176.
106. Pirracchio R, Deye N, Lukaszewicz AC, et al. Impaired plasma B-type natriuretic peptide clearance in human septic shock. Crit Care Med 2008; 36: 2542-2546.
107. de Bree FM, Burbach JP. Structure-function relationships of the vasopressin prohormone domains. Cell Mol Neurobiol 1998; 18: 173-191.
108. Müller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007; 37: 145-152.
109. Krüger S, Papassotiriou J, Marre R, et al. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. Intensive Care Med 2007; 33: 2069-2078.
110. Christ-Crain M, Stolz D, Jutla S, et al. Free and total cortisol levels as predicts of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 176: 913-920.
111. Brauner JS, Rohde LE, Clausell N. Circulating endothelin-I and tumor necrosis factor-a: early predictors of mortality in patients with septic shock. Intensive Care Med 2000; 26: 305-313.
112. Ramírez P, Ferrer M, MartíV, et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med 2011; 39: 2211-2217.
113. Krüger S, Ewig S, Kunde J, et al. Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term mortality in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax 2010; 65: 208-214.
114. Rello J, Lisboa T, Lujan M, et al. Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest 2009; 136: 832-840.
115. Peters RP, de Boer RF, Schuurman T, et al. Streptococcus pneumoniaeDNA load in blood as a marker of infection in patients with community-acquired pneumonia. J Clin Microbiol 2009; 47: 3308-3312.
116. Lisboa T, Waterer G, Rello J. We should be measuring genomic bacterial load and virulence factors. Crit Care Med 2010; 38: Suppl. 10, S656-S662.